DOCSLIB.ORG

Genome-Wide CRISPR Screen for PARKIN Regulators Reveals Transcriptional Repression As a Determinant of Mitophagy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genome-Wide CRISPR Screen for PARKIN Regulators Reveals Transcriptional Repression As a Determinant of Mitophagy Genome-wide CRISPR screen for PARKIN regulators PNAS PLUS reveals transcriptional repression as a determinant of mitophagy Christoph Pottinga, Christophe Crochemorea, Francesca Morettia, Florian Nigscha, Isabel Schmidta, Carole Mannevillea, Walter Carbonea, Judith Knehra, Rowena DeJesusb, Alicia Lindemanb, Rob Maherb, Carsten Russb, Gregory McAllisterb, John S. Reece-Hoyesb, Gregory R. Hoffmanb, Guglielmo Romaa, Matthias Müllera, Andreas W. Sailera, and Stephen B. Helliwella,1 aNovartis Institutes for BioMedical Research, Basel CH 4002, Switzerland; and bNovartis Institutes for BioMedical Research, Cambridge, MA 02139 Edited by Beth Levine, The University of Texas Southwestern, Dallas, TX, and approved November 29, 2017 (received for review June 20, 2017) PARKIN, an E3 ligase mutated in familial Parkinson’s disease, promotes how these proteins are themselves regulated, is important for mitophagy by ubiquitinating mitochondrial proteins for efficient the further understanding of mitophagy and the pathogenesis engagement of the autophagy machinery. Specifically, PARKIN- of Parkinson’s disease. synthesized ubiquitin chains represent targets for the PINK1 kinase Previous studies identified regulators of PINK1/PARKIN- generating phosphoS65-ubiquitin (pUb), which constitutes the mitoph- mediated mitophagy employing RNAi screens with damage- agy signal. Physiological regulation of PARKIN abundance, however, induced mitochondrial translocation of overexpressed GFP- and the impact on pUb accumulation are poorly understood. Using PARKIN as a mitophagy proxy (12–15). These efforts pro- cells designed to discover physiological regulators of PARKIN abun- foundly advanced the understanding of mitophagy regulation; dance, we performed a pooled genome-wide CRISPR/Cas9 knockout however, little is known about how cells set the threshold for screen. Testing identified genes individually resulted in a list of mitophagy to proceed. In this regard, cellular regulation of 53 positive and negative regulators. A transcriptional repressor net- PARKIN abundance is of particular interest as it may represent work including THAP11 was identified and negatively regulates en- a mechanism to tune the progression of mitophagy by impacting CELL BIOLOGY dogenous PARKIN abundance. RNAseq analysis revealed the pUb accumulation to adapt to physiological state changes. PARKIN-encoding locus as a prime THAP11 target, and THAP11 CRISPR The CRISPR/Cas9 gene-editing technology as a screening knockout in multiple cell types enhanced pUb accumulation. Thus, our tool appears to be superior to RNAi in most cases of lethality screens work demonstrates the critical role of PARKIN abundance, identifies (16–18) and in phenotypic screens (19). Using cells expressing a regulating genes, and reveals a link between transcriptional repres- PARKIN reporter protein from the endogenous PARK2 pro- sion and mitophagy, which is also apparent in human induced plurip- moter and in which steady state PARKIN levels dictate the otent stem cell-derived neurons, a disease-relevant cell type. kinetics of pUb accumulation, a phenotypic genome-wide CRISPR/Cas9 pooled screen was performed and resulted in a PARKIN | mitophagy | phosphoubiquitin | THAP11 | genome-wide screen list of 53 positive and negative regulators. We show that transcriptional ysfunction of mitochondria is implicated in aging and hu- Significance Dman disease, including Parkinson’s disease. Mitochondrial functionality is assured by a hierarchical system of interdepen- In mitophagy, damaged mitochondria are targeted for disposal dent cellular quality-control mechanisms acting at molecular or by the autophagy machinery. PARKIN promotes signaling of organellar levels to allow rapid adaptation to mitochondrial stress PARK2 mitochondrial damage to the autophagy machinery for en- and damage (1). The E3 ligase PARKIN (encoded by the gagement, and PARKIN mutations cause Parkinson’s disease, gene) takes on the role of a major sentinel that integrates multiple possibly because damaged mitochondria accumulate in neu- quality-control mechanisms ranging from facilitating proteasomal rons. Because regulation of PARKIN abundance and the impact degradation of mitochondrial proteins to suppressing mitochon- on signaling are poorly understood, we performed a genetic drial antigen presentation (2, 3). screen to identify PARKIN abundance regulators. Both positive ’ PARKIN s best-characterized role in mitochondrial quality and negative regulators were identified and will help us to control is in PINK1/PARKIN-mediated mitophagy where PARKIN further understand mitophagy and Parkinson’s disease. We acts in concert with the PINK1 kinase in the signaling of mitochon- show that some of the identified genes negatively regulate drial damage to the autophagy machinery. Herein, PINK1 accumu- PARKIN gene expression, which impacts signaling of mito- lates on the surface of dysfunctional mitochondria and recruits and chondrial damage in mitophagy. This link between transcrip- activates cytosolic PARKIN. Preformed ubiquitin chains on multiple tional repression and mitophagy is also apparent in neurons in mitochondrial surface proteins are extended by activated PARKIN culture, bearing implications for disease. and S65-phosphorylated by PINK1 (4–7). The accumulation of S65- phosphorylated ubiquitin (pUb) on mitochondria constitutes the Author contributions: C.P. and S.B.H. designed research; C.P., C.C., F.M., F.N., I.S., C.M., signaling mechanism to engage the autophagy machinery for selective W.C., J.K., R.D., A.L., and R.M. performed research; C.P. and F.N. contributed new re- agents/analytic tools; C.P., C.C., F.M., F.N., W.C., J.K., C.R., G.M., J.S.R.-H., G.R.H., G.R., clearance of dysfunctional mitochondria (8). The efficiency of M.M., A.W.S., and S.B.H. analyzed data; and C.P. and S.B.H. wrote the paper. mitophagy appears to depend on the pUb signal: while PINK1 Conflict of interest statement: All authors are employees of, and may own shares of, generated pUb from preformed chains in the absence of PARKIN Novartis Pharma AG. can induce some mitophagy, the presence of PARKIN amplifies the This article is a PNAS Direct Submission. accumulation of pUb via a feed-forward mechanism and enhances This open access article is distributed under Creative Commons Attribution-NonCommercial- mitophagy (8, 9). Mutations in both PINK1 and PARKIN are a cause NoDerivatives License 4.0 (CC BY-NC-ND). of familial Parkinson’s disease, suggesting that compromised 1To whom correspondence should be addressed. Email: [email protected]. mitophagy is an underlying feature (10, 11). Thus, the thorough This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. understanding of how these proteins regulate mitophagy, and 1073/pnas.1711023115/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1711023115 PNAS Early Edition | 1of10 Downloaded by guest on October 1, 2021 repression negatively regulates endogenous PARKIN steady-state contains enhancer and repressor sites for physiological control of level. In particular, THAP11 depletion affects both PARKIN pro- expression (20) (Fig. S1B). We selected a clone showing the lowest tein levels and pUb accumulation in multiple cell types. Finally, discrete GFP-signal in flow cytometry (endoGFP-PARKIN cells) human induced pluripotent stem cell (iPSC)-derived inducible (Fig. 1A). The fluorescence signal is below the detection threshold Neurogenin 2 (iNGN2) neurons in which THAP11 was targeted of conventional fluorescence microscopy, but is GFP-PARKIN– by CRISPR/Cas9 display de-repression of PARK2 transcription dependent because PARKIN-directed single guide RNAs (sgRNAs) and enhanced pUb accumulation, demonstrating the impact of resulted in the concomitant loss of GFP-PARKIN protein and GFP- PARKIN-level regulation in a relevant cell type. fluorescence (Fig. 1 B and C). While endogenous PARKIN protein levels in the parental cells were near the detection threshold, GFP- Results PARKIN was readily detectable, likely reflecting multiple transgene PARKIN Levels Dictate Kinetics of pUb Accumulation. To assess the insertions (Fig. 1D). effects of cellular PARKIN abundance on downstream processes, We then examined the downstream effects of PARKIN-level we generated cellular models with different levels of PARKIN ex- alterations by assessing the accumulation of pUb upon mito- pression. HEK293-based JumpIN TI 293 cells expressing endoge- chondrial damage in parental and endoGFP-PARKIN cells, nous PARKIN were infected with lentiviruses for stable integration additionally infected with either a PARK2-specific or a control of Cas9 to enable gene editing and PARKIN depletion (parental [scrambled (SCR)] sgRNA. After treatment of parental cells cells) (Fig. S1A). Next, we aimed at generating cells with mildly transduced with control viruses with the mitochondria-damaging elevated PARKIN expression additionally amenable to functional agent carbonyl cyanide m-chlorophenyl hydrazone (CCCP) for screening for physiological regulators of PARKIN. Thus, parental 6h,α-pUb signals appeared that were absent in DMSO-treated cells were transfected with a transgene encoding GFP-PARKIN samples (Fig. 1E), indicating the initiation of mitophagy. pUb under the control of a large PARK2 promoter fragment, which accumulation in endoGFP-PARKIN cells was robustly induced endo AB C DGFP- parental PARKIN endoGFP-PARKIN sgRNA vs. SCR endoGFP-PARKIN GFP-negative parental PARK2 #i PARK2 #ii Day 8 Day 15 300 250 SCR PARK2#i SCR PARK2#i Day 8 200
Load more

Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Sequence Overlap Between Autosomal and Sex-Linked Probes on the Illumina Humanmethylation27 Microarray
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Genomics 97 (2011) 214–222 Contents lists available at ScienceDirect Genomics journal homepage: www.elsevier.com/locate/ygeno Sequence overlap between autosomal and sex-linked probes on the Illumina HumanMethylation27 microarray Yi-an Chen a,b, Sanaa Choufani a, Jose Carlos Ferreira a,b, Daria Grafodatskaya a, Darci T. Butcher a, Rosanna Weksberg a,b,⁎ a Program in Genetics and Genome Biology, Hospital for Sick Children Research Institute, Toronto, Ontario, Canada b Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada article info abstract Article history: The Illumina Infinium HumanMethylation27 BeadChip (Illumina 27k) microarray is a high-throughput Received 12 August 2010 platform capable of interrogating the human DNA methylome. In a search for autosomal sex-specific DNA Accepted 18 December 2010 methylation using this microarray, we discovered autosomal CpG loci showing significant methylation Available online 4 January 2011 differences between the sexes. However, we found that the majority of these probes cross-reacted with sequences from sex chromosomes. Moreover, we determined that 6–10% of the microarray probes are non- Keywords: specific and map to highly homologous genomic sequences. Using probes targeting different CpGs that are Illumina Infinium HumanMethylation 27 BeadChip exact duplicates of each other, we investigated the precision of these repeat measurements and concluded Non-specific cross-reactive probe that the overall precision of this microarray is excellent. In addition, we identified a small number of probes Sex-specific DNA methylation targeting CpGs that include single-nucleotide polymorphisms.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • 1 Silencing Branched-Chain Ketoacid Dehydrogenase Or
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.21.960153; this version posted February 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Silencing branched-chain ketoacid dehydrogenase or treatment with branched-chain ketoacids ex vivo inhibits muscle insulin signaling Running title: BCKAs impair insulin signaling Dipsikha Biswas1, PhD, Khoi T. Dao1, BSc, Angella Mercer1, BSc, Andrew Cowie1 , BSc, Luke Duffley1, BSc, Yassine El Hiani2, PhD, Petra C. Kienesberger1, PhD, Thomas Pulinilkunnil1†, PhD 1Department of Biochemistry and Molecular Biology, Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada, 2Department of Physiology and Biophysics, Dalhousie University, Halifax, Nova Scotia, Canada. †Correspondence to Thomas Pulinilkunnil, PhD Department of Biochemistry and Molecular Biology, Faculty of Medicine, Dalhousie University Dalhousie Medicine New Brunswick, 100 Tucker Park Road, Saint John E2L4L5, New Brunswick, Canada. Telephone: (506) 636-6973; Fax: (506) 636-6001; email: [email protected]. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.02.21.960153; this version posted February 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International
    [Show full text]
  • Application of a MYC Degradation
    SCIENCE SIGNALING | RESEARCH ARTICLE CANCER Copyright © 2019 The Authors, some rights reserved; Application of a MYC degradation screen identifies exclusive licensee American Association sensitivity to CDK9 inhibitors in KRAS-mutant for the Advancement of Science. No claim pancreatic cancer to original U.S. Devon R. Blake1, Angelina V. Vaseva2, Richard G. Hodge2, McKenzie P. Kline3, Thomas S. K. Gilbert1,4, Government Works Vikas Tyagi5, Daowei Huang5, Gabrielle C. Whiten5, Jacob E. Larson5, Xiaodong Wang2,5, Kenneth H. Pearce5, Laura E. Herring1,4, Lee M. Graves1,2,4, Stephen V. Frye2,5, Michael J. Emanuele1,2, Adrienne D. Cox1,2,6, Channing J. Der1,2* Stabilization of the MYC oncoprotein by KRAS signaling critically promotes the growth of pancreatic ductal adeno- carcinoma (PDAC). Thus, understanding how MYC protein stability is regulated may lead to effective therapies. Here, we used a previously developed, flow cytometry–based assay that screened a library of >800 protein kinase inhibitors and identified compounds that promoted either the stability or degradation of MYC in a KRAS-mutant PDAC cell line. We validated compounds that stabilized or destabilized MYC and then focused on one compound, Downloaded from UNC10112785, that induced the substantial loss of MYC protein in both two-dimensional (2D) and 3D cell cultures. We determined that this compound is a potent CDK9 inhibitor with a previously uncharacterized scaffold, caused MYC loss through both transcriptional and posttranslational mechanisms, and suppresses PDAC anchorage- dependent and anchorage-independent growth. We discovered that CDK9 enhanced MYC protein stability 62 through a previously unknown, KRAS-independent mechanism involving direct phosphorylation of MYC at Ser .
    [Show full text]
  • Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Nan Hu1, Mitsutaka Kadota2, Huaitian Liu2, Christian C
    Published OnlineFirst February 8, 2016; DOI: 10.1158/0008-5472.CAN-15-0338 Cancer Integrated Systems and Technologies Research Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Nan Hu1, Mitsutaka Kadota2, Huaitian Liu2, Christian C. Abnet1, Hua Su1, Hailong Wu2, Neal D. Freedman1, Howard H. Yang2, Chaoyu Wang1, Chunhua Yan2, Lemin Wang1, Sheryl Gere2, Amy Hutchinson1,3, Guohong Song2, Yuan Wang4, Ti Ding4, You-Lin Qiao5, Jill Koshiol1, Sanford M. Dawsey1, Carol Giffen6, Alisa M. Goldstein1, Philip R. Taylor1, and Maxwell P. Lee2 Abstract Gastric cancer and esophageal cancer are the second and that oxidation of guanine may be a potential mechanism sixth leading causes of cancer-related death worldwide. Multi- underlying cancer mutagenesis. Furthermore, we identified ple genomic alterations underlying gastric cancer and esoph- genes with mutations in gastric cancer and ESCC, including ageal squamous cell carcinoma (ESCC) have been identified, well-known cancer genes, TP53, JAK3, BRCA2, FGF2, FBXW7, but the full spectrum of genomic structural variations and MSH3, PTCH, NF1, ERBB2, and CHEK2, and potentially novel mutations have yet to be uncovered. Here, we report the results cancer-associated genes, KISS1R, AMH, MNX1, WNK2,and of whole-genome sequencing of 30 samples comprising tumor PRKRIR. Finally, we identified recurrent chromosome altera- and blood from 15 patients, four of whom presented with tions in at least 30% of tumors in genes, including MACROD2, ESCC, seven with gastric cardia adenocarcinoma (GCA), and FHIT,andPARK2 that were often intragenic deletions. These four with gastric noncardia adenocarcinoma. Analyses revealed structural alterations were validated using the The Cancer that an A>CmutationwascommoninGCA,andinadditionto Genome Atlas dataset.
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • 1 Silencing Branched-Chain Ketoacid Dehydrogenase Or
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.21.960153; this version posted February 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Silencing branched-chain ketoacid dehydrogenase or treatment with branched-chain ketoacids ex vivo inhibits muscle insulin signaling Running title: BCKAs impair insulin signaling Dipsikha Biswas1, PhD, Khoi T. Dao1, BSc, Angella Mercer1, BSc, Andrew Cowie1 , BSc, Luke Duffley1, BSc, Yassine El Hiani2, PhD, Petra C. Kienesberger1, PhD, Thomas Pulinilkunnil1†, PhD 1Department of Biochemistry and Molecular Biology, Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada, 2Department of Physiology and Biophysics, Dalhousie University, Halifax, Nova Scotia, Canada. †Correspondence to Thomas Pulinilkunnil, PhD Department of Biochemistry and Molecular Biology, Faculty of Medicine, Dalhousie University Dalhousie Medicine New Brunswick, 100 Tucker Park Road, Saint John E2L4L5, New Brunswick, Canada. Telephone: (506) 636-6973; Fax: (506) 636-6001; email: [email protected]. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.02.21.960153; this version posted February 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. Large-scale quantitative phosphoproteomic profiling was performed on paired vehicle- and hormone-treated mTAL-enriched suspensions (n=3). A total of 654 unique phosphopeptides corresponding to 374 unique phosphoproteins were identified. The peptide sequence, phosphorylation site(s), and the corresponding protein name, gene symbol, and RefSeq Accession number are reported for each phosphopeptide identified in any one of three experimental pairs. For those 414 phosphopeptides that could be quantified in all three experimental pairs, the mean Hormone:Vehicle abundance ratio and corresponding standard error are also reported. Peptide Sequence column: * = phosphorylated residue Site(s) column: ^ = ambiguously assigned phosphorylation site Log2(H/V) Mean and SE columns: H = hormone-treated, V = vehicle-treated, n/a = peptide not observable in all 3 experimental pairs Sig. column: * = significantly changed Log 2(H/V), p<0.05 Log (H/V) Log (H/V) # Gene Symbol Protein Name Refseq Accession Peptide Sequence Site(s) 2 2 Sig. Mean SE 1 Aak1 AP2-associated protein kinase 1 NP_001166921 VGSLT*PPSS*PK T622^, S626^ 0.24 0.95 PREDICTED: ATP-binding cassette, sub-family A 2 Abca12 (ABC1), member 12 XP_237242 GLVQVLS*FFSQVQQQR S251^ 1.24 2.13 3 Abcc10 multidrug resistance-associated protein 7 NP_001101671 LMT*ELLS*GIRVLK T464, S468 -2.68 2.48 4 Abcf1 ATP-binding cassette sub-family F member 1 NP_001103353 QLSVPAS*DEEDEVPVPVPR S109 n/a n/a 5 Ablim1 actin-binding LIM protein 1 NP_001037859 PGSSIPGS*PGHTIYAK S51 -3.55 1.81 6 Ablim1 actin-binding
    [Show full text]
  • EGL Test Description
    2460 Mountain Industrial Boulevard | Tucker, Georgia 30084 Phone: 470-378-2200 or 855-831-7447 | Fax: 470-378-2250 eglgenetics.com Autism Spectrum Disorders: Tier 2 Deletion/Duplication Panel Test Code: MD021 Turnaround time: 2 weeks CPT Codes: 81161 x1, 81323 x1, 81403 x1, 81404 x1, 81405 x1, 81406 x1 Condition Description Genetics of Autism Spectrum Disorders Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders which include autism, pervasive developmental delay-not otherwise specified (PDD-NOS), and Asperger syndrome. ASDs are characterized by impairments in social relationships, variable degrees of language and communication deficits, and repetitive behaviors and/or a narrow range of interests. The age of onset is prior to age 3 with a variable clinical presentation, ranging in severity both amongst individuals as well as amongst the various subtypes of ASDs. Additional clinical features may also be observed in individuals with an ASD, such as intellectual disability (up to ~50%) and seizures (~25%). Known genetic causes of autism include cytogenetically visible chromosome abnormalities (3-5%), copy number variants – which include submicroscopic deletions and duplications (~6-7%), and single gene disorders (~5%). EGL Genetics’s integrated testing strategy allows for a comprehensive cytogenetics, metabolic, and molecular analysis of ASD in your patient. For a summary of autism testing at EGL, please click here. *Please note that some genes on this panel are associated with additional phenotypes. References: Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators and the CDC (2009). MMWR Surveill Summ, 58:1-20. Bolton et al. (2011). Br J Psychiatry, 198:289-294.
    [Show full text]
  • Amplification of the BRCA2 Pathway Gene EMSY in Sporadic Breast Cancer Is Related to Negative Outcome
    Vol. 10, 5785–5791, September 1, 2004 Clinical Cancer Research 5785 Amplification of the BRCA2 Pathway Gene EMSY in Sporadic Breast Cancer Is Related to Negative Outcome Carmen Rodriguez,1 Luke Hughes-Davies,2 INTRODUCTION He´le`ne Valle`s,1 Be´atrice Orsetti,1 DNA amplification is a common mechanism of oncogenic Marguerite Cuny,1 Lisa Ursule,1 activation in human tumors, and band q13 of chromosome 11 is a frequent site of genetic aberration in a number of human Tony Kouzarides,2 and Charles Theillet1 malignancies, particularly breast and head and neck cancers (1). 1 Ge´notype et Phe´notypes Tumoraux E 229 INSERM, Centre Val Several candidate oncogenes have been proposed, among which d’Aurelle, Montpellier, France; 2Cancer Research UK/Wellcome Institute, Cambridge, United Kingdom only CCND1 and EMS1 meet the criteria for genes activated by DNA amplification (2). Both genes map to chromosome 11q13.3, 0.8 Mb apart, with CCND1 occupying a more centro- ABSTRACT meric position than EMS1 (3). Because CCND1 is frequently DNA amplification at band q13 of chromosome 11 is rearranged by chromosomal translocations in hematologic ma- common in breast cancer, and CCND1 and EMS1 remain lignancies and overexpressed in several human tumors, this gene the strongest candidate genes. However, amplification pat- has been considered the principal target for DNA amplification terns are consistent with the existence of four cores of am- at 11q13 (4). However, some findings suggested that 11q13 plification, suggesting the involvement of additional genes. amplification could be more complex. On the basis of the Here we present evidence strongly suggesting the involve- recently completed genome map, the 11q13 amplification do- ment of the recently characterized EMSY gene in the for- main spans up to 7 Mb and the existence of four distinct cores mation of the telomeric amplicon.
    [Show full text]